Scaled Average Bioequivalence [Regulatives / Guidelines]

posted by graveendranath – 2010-01-06 08:36 (6012 d 17:15 ago) – Posting: # 4563
Views: 7,594

Dear Helmut,

We want to conduct a study with partial replicated design (Reference twice) for Europe regulatory. My doubt is

1. Does the Europe Regulatory accepts the Scaled Average Bioequivalence method for highly variable drugs?
2. If we can show that the Intra cv for reference product is > 30% then can we use wider limits (75-133)?

Thank You

Rgds
Raveendranath

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
161 visitors (0 registered, 161 guests [including 35 identified bots]).
Forum time: 02:52 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5